ID   GBP2_HUMAN              Reviewed;         591 AA.
AC   P32456; Q6GPH0; Q6IAU2; Q86TB0;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   14-APR-2009, sequence version 3.
DT   28-JUN-2023, entry version 188.
DE   RecName: Full=Guanylate-binding protein 2;
DE            EC=3.6.5.- {ECO:0000269|PubMed:8706832};
DE   AltName: Full=GTP-binding protein 2 {ECO:0000303|PubMed:8706832};
DE            Short=GBP-2 {ECO:0000303|PubMed:8706832};
DE            Short=HuGBP-2;
DE   AltName: Full=Guanine nucleotide-binding protein 2 {ECO:0000303|PubMed:8706832};
DE   AltName: Full=Interferon-induced guanylate-binding protein 2;
DE   Flags: Precursor;
GN   Name=GBP2 {ECO:0000303|PubMed:8706832, ECO:0000312|HGNC:HGNC:4183};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ALA-285.
RC   TISSUE=Keratinocyte;
RX   PubMed=1715024; DOI=10.1128/mcb.11.9.4717-4725.1991;
RA   Cheng Y.-S.E., Patterson C.E., Staeheli P.;
RT   "Interferon-induced guanylate-binding proteins lack an N(T)KXD consensus
RT   motif and bind GMP in addition to GDP and GTP.";
RL   Mol. Cell. Biol. 11:4717-4725(1991).
RN   [2]
RP   SEQUENCE REVISION.
RC   TISSUE=Foreskin;
RA   Schwemmle M.;
RL   Submitted (SEP-1991) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ALA-285 AND GLY-303.
RC   TISSUE=Spinal cord;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ALA-285 AND GLY-303.
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ALA-285 AND GLY-303.
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS ALA-285 AND
RP   GLY-303.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=8706832; DOI=10.1016/0014-5793(96)00628-x;
RA   Neun R., Richter M.F., Staeheli P., Schwemmle M.;
RT   "GTPase properties of the interferon-induced human guanylate-binding
RT   protein 2.";
RL   FEBS Lett. 390:69-72(1996).
RN   [10]
RP   SUBCELLULAR LOCATION, AND INDUCTION.
RX   PubMed=17266443; DOI=10.1089/jir.2007.0086;
RA   Tripal P., Bauer M., Naschberger E., Mortinger T., Hohenadl C., Cornali E.,
RA   Thurau M., Sturzl M.;
RT   "Unique features of different members of the human guanylate-binding
RT   protein family.";
RL   J. Interferon Cytokine Res. 27:44-52(2007).
RN   [11]
RP   SUBCELLULAR LOCATION, ISOPRENYLATION AT CYS-588, METHYLATION AT CYS-588,
RP   DIMERIZATION, AND MUTAGENESIS OF 588-CYS--LEU-591.
RX   PubMed=21151871; DOI=10.1371/journal.pone.0014246;
RA   Britzen-Laurent N., Bauer M., Berton V., Fischer N., Syguda A.,
RA   Reipschlager S., Naschberger E., Herrmann C., Sturzl M.;
RT   "Intracellular trafficking of guanylate-binding proteins is regulated by
RT   heterodimerization in a hierarchical manner.";
RL   PLoS ONE 5:E14246-E14246(2010).
RN   [12]
RP   UBIQUITINATION (MICROBIAL INFECTION).
RX   PubMed=29024643; DOI=10.1016/j.chom.2017.09.007;
RA   Wandel M.P., Pathe C., Werner E.I., Ellison C.J., Boyle K.B.,
RA   von der Malsburg A., Rohde J., Randow F.;
RT   "GBPs inhibit motility of Shigella flexneri but are targeted for
RT   degradation by the bacterial ubiquitin ligase IpaH9.8.";
RL   Cell Host Microbe 22:507-518(2017).
RN   [13]
RP   UBIQUITINATION (MICROBIAL INFECTION).
RX   PubMed=29144452; DOI=10.1038/nature24467;
RA   Li P., Jiang W., Yu Q., Liu W., Zhou P., Li J., Xu J., Xu B., Wang F.,
RA   Shao F.;
RT   "Ubiquitination and degradation of GBPs by a Shigella effector to suppress
RT   host defence.";
RL   Nature 551:378-383(2017).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, ISOPRENYLATION AT CYS-588, AND MUTAGENESIS
RP   OF CYS-588.
RX   PubMed=31091448; DOI=10.1016/j.celrep.2019.04.063;
RA   Braun E., Hotter D., Koepke L., Zech F., Gross R., Sparrer K.M.J.,
RA   Mueller J.A., Pfaller C.K., Heusinger E., Wombacher R., Sutter K.,
RA   Dittmer U., Winkler M., Simmons G., Jakobsen M.R., Conzelmann K.K.,
RA   Poehlmann S., Muench J., Fackler O.T., Kirchhoff F., Sauter D.;
RT   "Guanylate-binding proteins 2 and 5 exert broad antiviral activity by
RT   inhibiting furin-mediated processing of viral envelope proteins.";
RL   Cell Rep. 27:2092-2104(2019).
RN   [15] {ECO:0007744|PDB:7E58}
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS).
RX   PubMed=33876762; DOI=10.1073/pnas.2022269118;
RA   Cui W., Braun E., Wang W., Tang J., Zheng Y., Slater B., Li N., Chen C.,
RA   Liu Q., Wang B., Li X., Duan Y., Xiao Y., Ti R., Hotter D., Ji X.,
RA   Zhang L., Cui J., Xiong Y., Sauter D., Wang Z., Kirchhoff F., Yang H.;
RT   "Structural basis for GTP-induced dimerization and antiviral function of
RT   guanylate-binding proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
CC   -!- FUNCTION: Interferon (IFN)-inducible GTPase that plays important roles
CC       in innate immunity against a diverse range of bacterial, viral and
CC       protozoan pathogens (PubMed:31091448). Hydrolyzes GTP to GMP in 2
CC       consecutive cleavage reactions, but the major reaction product is GDP
CC       (PubMed:8706832). Following infection, recruited to the pathogen-
CC       containing vacuoles or vacuole-escaped bacteria and acts as a positive
CC       regulator of inflammasome assembly by promoting the release of
CC       inflammasome ligands from bacteria (By similarity). Acts by promoting
CC       lysis of pathogen-containing vacuoles, releasing pathogens into the
CC       cytosol (By similarity). Following pathogen release in the cytosol,
CC       promotes recruitment of proteins that mediate bacterial cytolysis: this
CC       liberates ligands that are detected by inflammasomes, such as
CC       lipopolysaccharide (LPS) that activates the non-canonical CASP4/CASP11
CC       inflammasome or double-stranded DNA (dsDNA) that activates the AIM2
CC       inflammasome (By similarity). Confers protection to the protozoan
CC       pathogen Toxoplasma gondii (By similarity). Independently of its GTPase
CC       activity, acts as an inhibitor of various viruses infectivity, such as
CC       HIV-1, Zika and influenza A viruses, by inhibiting FURIN-mediated
CC       maturation of viral envelope proteins (PubMed:31091448).
CC       {ECO:0000250|UniProtKB:Q9Z0E6, ECO:0000269|PubMed:31091448,
CC       ECO:0000269|PubMed:8706832}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=GTP + H2O = GDP + H(+) + phosphate; Xref=Rhea:RHEA:19669,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:37565,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:58189;
CC         Evidence={ECO:0000269|PubMed:8706832};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=313 uM for GTP {ECO:0000269|PubMed:8706832};
CC   -!- SUBUNIT: Homodimer; homodimerization occurs upon GTP-binding and is
CC       required for the association with membranous structures
CC       (PubMed:21151871). Heterodimer with other family members, including
CC       GBP1, GBP3, GBP4 and GBP5 (PubMed:21151871).
CC       {ECO:0000269|PubMed:21151871}.
CC   -!- INTERACTION:
CC       P32456; P32455: GBP1; NbExp=9; IntAct=EBI-714388, EBI-2869161;
CC       P32456; P32456: GBP2; NbExp=5; IntAct=EBI-714388, EBI-714388;
CC       P32456; Q9H0R5: GBP3; NbExp=3; IntAct=EBI-714388, EBI-2798916;
CC       P32456; Q96PP9: GBP4; NbExp=2; IntAct=EBI-714388, EBI-20840650;
CC       P32456; Q96PP8: GBP5; NbExp=7; IntAct=EBI-714388, EBI-749932;
CC       P32456; PRO_0000037548 [Q9WMX2]; Xeno; NbExp=2; IntAct=EBI-714388, EBI-6863741;
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle membrane
CC       {ECO:0000250|UniProtKB:Q9Z0E6}; Lipid-anchor
CC       {ECO:0000269|PubMed:21151871}. Golgi apparatus membrane
CC       {ECO:0000269|PubMed:21151871, ECO:0000269|PubMed:31091448}; Lipid-
CC       anchor {ECO:0000269|PubMed:21151871}. Cytoplasm
CC       {ECO:0000269|PubMed:21151871}. Cytoplasm, perinuclear region
CC       {ECO:0000269|PubMed:21151871}. Note=GBP2-GBP5 dimers localize to the
CC       Golgi apparatus. {ECO:0000269|PubMed:21151871}.
CC   -!- INDUCTION: By IFNG/IFN-gamma during macrophage activation, and by TNF
CC       and IL1B. {ECO:0000269|PubMed:17266443}.
CC   -!- PTM: (Microbial infection) Ubiquitinated by S.flexneri IpaH9.8, leading
CC       to its degradation by the proteasome, thereby preventing its ability to
CC       promote host defense against bacterial infection.
CC       {ECO:0000269|PubMed:29024643, ECO:0000269|PubMed:29144452}.
CC   -!- PTM: Isoprenylation is required for proper subcellular location.
CC       {ECO:0000269|PubMed:21151871}.
CC   -!- SIMILARITY: Belongs to the TRAFAC class dynamin-like GTPase
CC       superfamily. GB1/RHD3 GTPase family. GB1 subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU01052}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M55543; AAA67323.1; -; mRNA.
DR   EMBL; AL832451; CAD89925.1; -; mRNA.
DR   EMBL; AK314325; BAG36973.1; -; mRNA.
DR   EMBL; CR457062; CAG33343.1; -; mRNA.
DR   EMBL; AC104459; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471097; EAW73146.1; -; Genomic_DNA.
DR   EMBL; BC073163; AAH73163.1; -; mRNA.
DR   CCDS; CCDS719.1; -.
DR   PIR; S70524; S70524.
DR   RefSeq; NP_004111.2; NM_004120.4.
DR   PDB; 6VKJ; X-ray; 2.10 A; A=5-309.
DR   PDB; 7E58; X-ray; 2.60 A; A/B=1-591.
DR   PDB; 7M1S; X-ray; 2.91 A; A=1-591.
DR   PDBsum; 6VKJ; -.
DR   PDBsum; 7E58; -.
DR   PDBsum; 7M1S; -.
DR   AlphaFoldDB; P32456; -.
DR   SMR; P32456; -.
DR   BioGRID; 108904; 52.
DR   IntAct; P32456; 37.
DR   MINT; P32456; -.
DR   STRING; 9606.ENSP00000359497; -.
DR   iPTMnet; P32456; -.
DR   PhosphoSitePlus; P32456; -.
DR   BioMuta; GBP2; -.
DR   DMDM; 226694187; -.
DR   EPD; P32456; -.
DR   jPOST; P32456; -.
DR   MassIVE; P32456; -.
DR   MaxQB; P32456; -.
DR   PaxDb; P32456; -.
DR   PeptideAtlas; P32456; -.
DR   ProteomicsDB; 54878; -.
DR   Antibodypedia; 33611; 441 antibodies from 29 providers.
DR   DNASU; 2634; -.
DR   Ensembl; ENST00000370466.4; ENSP00000359497.3; ENSG00000162645.13.
DR   Ensembl; ENST00000464839.5; ENSP00000434282.1; ENSG00000162645.13.
DR   GeneID; 2634; -.
DR   KEGG; hsa:2634; -.
DR   MANE-Select; ENST00000370466.4; ENSP00000359497.3; NM_004120.5; NP_004111.2.
DR   UCSC; uc001dmz.3; human.
DR   AGR; HGNC:4183; -.
DR   CTD; 2634; -.
DR   DisGeNET; 2634; -.
DR   GeneCards; GBP2; -.
DR   HGNC; HGNC:4183; GBP2.
DR   HPA; ENSG00000162645; Low tissue specificity.
DR   MIM; 600412; gene.
DR   neXtProt; NX_P32456; -.
DR   OpenTargets; ENSG00000162645; -.
DR   PharmGKB; PA28597; -.
DR   VEuPathDB; HostDB:ENSG00000162645; -.
DR   eggNOG; KOG2037; Eukaryota.
DR   GeneTree; ENSGT00940000162297; -.
DR   HOGENOM; CLU_018608_2_2_1; -.
DR   InParanoid; P32456; -.
DR   OMA; FINDETY; -.
DR   OrthoDB; 5309032at2759; -.
DR   PhylomeDB; P32456; -.
DR   TreeFam; TF331602; -.
DR   PathwayCommons; P32456; -.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   SignaLink; P32456; -.
DR   BioGRID-ORCS; 2634; 22 hits in 1157 CRISPR screens.
DR   ChiTaRS; GBP2; human.
DR   GeneWiki; GBP2; -.
DR   GenomeRNAi; 2634; -.
DR   Pharos; P32456; Tbio.
DR   PRO; PR:P32456; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P32456; protein.
DR   Bgee; ENSG00000162645; Expressed in tendon of biceps brachii and 195 other tissues.
DR   Genevisible; P32456; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; ISS:UniProtKB.
DR   GO; GO:0030659; C:cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IDA:UniProt.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005525; F:GTP binding; IBA:GO_Central.
DR   GO; GO:0003924; F:GTPase activity; IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0140678; F:molecular function inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0002218; P:activation of innate immune response; ISS:UniProtKB.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEP:UniProtKB.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; ISS:UniProtKB.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IEP:UniProtKB.
DR   GO; GO:0071346; P:cellular response to type II interferon; IDA:UniProtKB.
DR   GO; GO:0051715; P:cytolysis in another organism; ISS:UniProtKB.
DR   GO; GO:0042742; P:defense response to bacterium; ISS:UniProtKB.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IBA:GO_Central.
DR   GO; GO:0042832; P:defense response to protozoan; IBA:GO_Central.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0140973; P:positive regulation of AIM2 inflammasome complex assembly; ISS:UniProtKB.
DR   GO; GO:0140639; P:positive regulation of pyroptosis; ISS:UniProtKB.
DR   GO; GO:0034504; P:protein localization to nucleus; IDA:UniProtKB.
DR   CDD; cd01851; GBP; 1.
DR   CDD; cd16269; GBP_C; 1.
DR   Gene3D; 1.20.1000.10; Guanylate-binding protein, C-terminal domain; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR030386; G_GB1_RHD3_dom.
DR   InterPro; IPR037684; GBP_C.
DR   InterPro; IPR003191; Guanylate-bd/ATL_C.
DR   InterPro; IPR036543; Guanylate-bd_C_sf.
DR   InterPro; IPR015894; Guanylate-bd_N.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR10751; GUANYLATE BINDING PROTEIN; 1.
DR   PANTHER; PTHR10751:SF112; GUANYLATE-BINDING PROTEIN 2; 1.
DR   Pfam; PF02263; GBP; 1.
DR   Pfam; PF02841; GBP_C; 1.
DR   SUPFAM; SSF48340; Interferon-induced guanylate-binding protein 1 (GBP1), C-terminal domain; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS51715; G_GB1_RHD3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Antimicrobial; Cytoplasm; Cytoplasmic vesicle;
KW   Golgi apparatus; GTP-binding; Hydrolase; Immunity; Innate immunity;
KW   Lipoprotein; Membrane; Methylation; Nucleotide-binding; Prenylation;
KW   Reference proteome; Ubl conjugation.
FT   CHAIN           1..588
FT                   /note="Guanylate-binding protein 2"
FT                   /id="PRO_0000190964"
FT   PROPEP          589..591
FT                   /note="Removed in mature form"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000370782"
FT   DOMAIN          35..276
FT                   /note="GB1/RHD3-type G"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01052"
FT   REGION          1..309
FT                   /note="GTPase domain (Globular)"
FT                   /evidence="ECO:0000250|UniProtKB:P32455"
FT   BINDING         45..52
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000250|UniProtKB:Q96PP8"
FT   BINDING         181..182
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000250|UniProtKB:Q96PP8"
FT   BINDING         245
FT                   /ligand="GTP"
FT                   /ligand_id="ChEBI:CHEBI:37565"
FT                   /evidence="ECO:0000250|UniProtKB:Q96PP8"
FT   MOD_RES         588
FT                   /note="Cysteine methyl ester"
FT                   /evidence="ECO:0000305|PubMed:21151871"
FT   LIPID           588
FT                   /note="S-geranylgeranyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:21151871,
FT                   ECO:0000305|PubMed:31091448"
FT   VARIANT         281
FT                   /note="S -> P (in dbSNP:rs2230336)"
FT                   /id="VAR_054815"
FT   VARIANT         285
FT                   /note="P -> A (in dbSNP:rs1803632)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:1715024, ECO:0000269|PubMed:17974005,
FT                   ECO:0000269|Ref.5, ECO:0000269|Ref.7"
FT                   /id="VAR_054816"
FT   VARIANT         303
FT                   /note="S -> G (in dbSNP:rs2230338)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:17974005, ECO:0000269|Ref.5,
FT                   ECO:0000269|Ref.7"
FT                   /id="VAR_054817"
FT   MUTAGEN         588..591
FT                   /note="Missing: No effect on subcellular location by
FT                   confocal microscopy, but loss of membrane-association by
FT                   subcellular fractionation."
FT                   /evidence="ECO:0000269|PubMed:21151871"
FT   MUTAGEN         588
FT                   /note="C->A: Loss of isoprenylation and of localization at
FT                   the Golgi apparatus."
FT                   /evidence="ECO:0000269|PubMed:31091448"
FT   CONFLICT        310
FT                   /note="M -> R (in Ref. 8; AAH73163)"
FT                   /evidence="ECO:0000305"
FT   STRAND          11..15
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   STRAND          20..23
FT                   /evidence="ECO:0007829|PDB:7E58"
FT   HELIX           25..32
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   STRAND          36..44
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   HELIX           51..59
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   HELIX           67..70
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   STRAND          71..74
FT                   /evidence="ECO:0007829|PDB:7M1S"
FT   STRAND          77..84
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   STRAND          86..88
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   STRAND          92..99
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   HELIX           104..106
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   TURN            111..113
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   HELIX           114..122
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   STRAND          124..133
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   HELIX           136..154
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   TURN            157..161
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   HELIX           167..172
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   STRAND          175..182
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   STRAND          187..189
FT                   /evidence="ECO:0007829|PDB:7E58"
FT   HELIX           196..204
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   STRAND          212..214
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   TURN            215..217
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   HELIX           218..227
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   STRAND          230..235
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   HELIX           242..250
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   HELIX           253..255
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   HELIX           258..274
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   TURN            281..283
FT                   /evidence="ECO:0007829|PDB:7E58"
FT   HELIX           288..303
FT                   /evidence="ECO:0007829|PDB:6VKJ"
FT   HELIX           310..340
FT                   /evidence="ECO:0007829|PDB:7E58"
FT   HELIX           348..368
FT                   /evidence="ECO:0007829|PDB:7E58"
FT   HELIX           374..376
FT                   /evidence="ECO:0007829|PDB:7E58"
FT   HELIX           377..412
FT                   /evidence="ECO:0007829|PDB:7E58"
FT   HELIX           414..421
FT                   /evidence="ECO:0007829|PDB:7E58"
FT   TURN            423..425
FT                   /evidence="ECO:0007829|PDB:7M1S"
FT   HELIX           430..447
FT                   /evidence="ECO:0007829|PDB:7E58"
FT   HELIX           455..465
FT                   /evidence="ECO:0007829|PDB:7E58"
FT   HELIX           467..476
FT                   /evidence="ECO:0007829|PDB:7E58"
FT   STRAND          478..480
FT                   /evidence="ECO:0007829|PDB:7M1S"
FT   HELIX           482..560
FT                   /evidence="ECO:0007829|PDB:7E58"
FT   HELIX           564..581
FT                   /evidence="ECO:0007829|PDB:7E58"
SQ   SEQUENCE   591 AA;  67209 MW;  B09B3C2F3C3E1EA2 CRC64;
     MAPEINLPGP MSLIDNTKGQ LVVNPEALKI LSAITQPVVV VAIVGLYRTG KSYLMNKLAG
     KKNGFSLGST VKSHTKGIWM WCVPHPKKPE HTLVLLDTEG LGDIEKGDNE NDSWIFALAI
     LLSSTFVYNS MGTINQQAMD QLHYVTELTD RIKANSSPGN NSVDDSADFV SFFPAFVWTL
     RDFTLELEVD GEPITADDYL ELSLKLRKGT DKKSKSFNDP RLCIRKFFPK RKCFVFDWPA
     PKKYLAHLEQ LKEEELNPDF IEQVAEFCSY ILSHSNVKTL SGGIPVNGPR LESLVLTYVN
     AISSGDLPCM ENAVLALAQI ENSAAVEKAI AHYEQQMGQK VQLPTETLQE LLDLHRDSER
     EAIEVFMKNS FKDVDQMFQR KLGAQLEARR DDFCKQNSKA SSDCCMALLQ DIFGPLEEDV
     KQGTFSKPGG YRLFTQKLQE LKNKYYQVPR KGIQAKEVLK KYLESKEDVA DALLQTDQSL
     SEKEKAIEVE RIKAESAEAA KKMLEEIQKK NEEMMEQKEK SYQEHVKQLT EKMERDRAQL
     MAEQEKTLAL KLQEQERLLK EGFENESKRL QKDIWDIQMR SKSLEPICNI L
//
